benazepril / Generic mfg. - LARVOL DELTA

Cilazapril and benazepril mitigate neurodegeneration and α-synuclein accumulation in a cellular model of parkinson's disease. (PubMed, Sci Rep) - "They modulated genetic pathways involved in dopaminergic signalling and showed high binding affinity for the AT1, AT2, D1A, D1B and D2 receptors. These findings suggest that cilazapril and benazepril exert multi-targeted protective effects that extend beyond simple antioxidant activity, and that they may be effective in treating or mitigating PD-related neurodegeneration."

Journal • CNS Disorders • Inflammation • Movement Disorders • Neuroblastoma • Oncology • Parkinson's Disease • Solid Tumor • IL10 • IL1B • TGFB1 • TNFA

The cost divide: Why veterinary medicinal products for dogs and cats in the EU cost more than their human equivalents. (PubMed, Res Vet Sci) - "Using comparative data on furosemide, amoxicillin, benazepril, and prednisone, the paper identifies how lack of public price negotiation, high VAT rates, concentrated market structure, and limitations in pet insurance coverage contribute to affordability challenges. The findings provide policy-relevant insights into how the EU could better align VMP pricing with principles of accessibility, sustainability, and innovation."

Journal

Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets and Sacubitril Alisartan Calcium Tablets Combined with Amlodipine Besylate Tablets (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Guangzhou Medical University; The Second Affiliated Hospital of Guangzhou Medical University

New trial • Cardiovascular • Hypertension

Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Army Medical University; Army Medical University

New trial • Glomerulonephritis • Renal Disease

Spectroscopic investigation of the competitive-allosteric-synergistic mechanism in the binding of benazepril/apigenin to bovine serum albumin. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Additionally, free sulfhydryl group (SH) assays indicated that both AP and BNZ protect free SH, with AP being the dominant factor. Esterase activity experiments confirmed that AP and BNZ synergistically inhibit BSA function."

Journal

Comparative Study on the Neuroprotective Effects of Perindopril and Benazepril in Experimentally-induced Chronic Mild Stress in Rats. (PubMed, J Neuroimmune Pharmacol) - "This study is among the first to highlight the antidepressant potential of benazepril, a non-centrally acting ACE inhibitor, and provides novel insights into its comparative efficacy against perindopril. These results collectively emphasize the broader therapeutic potential of ACE inhibitors in treating depression and underscore the need for further research to fully explore their underlying mechanisms and diverse applications in psychiatric disorders."

Clinical • Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mental Retardation • Mood Disorders • Psychiatry

Centrally Acting ACE Inhibition in SLE (clinicaltrials.gov) - P2 | N=36 | Active, not recruiting | Sponsor: Northwell Health | Trial completion date: Nov 2025 ➔ Mar 2026

Trial completion date • Cognitive Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Comparison of the effects of dual, triple, and quadruple medical therapy on cardiac death in a retrospective cohort of dogs with myxomatous mitral valve disease at American College of Veterinary Internal Medicine stage C: is more necessarily better? (PubMed, J Am Vet Med Assoc) - "To compare selected cardiac effects of dual therapy (DT; furosemide and pimobendan), triple therapy (TT; furosemide, pimobendan, and benazepril), and quadruple therapy (QT; furosemide, pimobendan, benazepril, and spironolactone) in dogs with myxomatous mitral valve disease at American College of Veterinary Internal Medicine (ACVIM) stage C. This was a multicenter retrospective study involving dogs with ACVIM stage C myxomatous mitral valve disease treated with DT, TT, or QT. In this study sample, QT and TT did not provide a higher clinically evident cardiac protective effect compared to DT. DT was not inferior to TT and QT in terms of cardiac death in dogs with ACVIM stage C myxomatous mitral valve disease included in this study."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Safety of Drugs in Breastfeeding Women With CKD. (PubMed, Kidney Int Rep) - "Among renin-angiotensin system inhibitors, enalapril and captopril are safe for breastfeeding. Based on limited evidence, quinapril, benazepril, candesartan, and valsartan are likely acceptable for use during breastfeeding. We found no compelling human data regarding the safety of other renin-angiotensin system inhibitors or sodium-glucose cotransporter type 2 (SGLT2) inhibitors, finerenone, sparsentan, or glucagon-like peptide-1 receptor agonists (GLP1RAs) in lactation. Immunosuppressive agents, including azathioprine, cyclosporine, tacrolimus, budesonide, rituximab, and eculizumab are acceptable for use during breastfeeding. Belimumab is most likely safe; however, data are limited...No studies were found on the safety of breastfeeding while on the newer complement inhibitors, including avacopan, ravulizumab, iptacopan, and pegcetacoplan...Human lactation data on the safety of most drugs used in the treatment of CKD are limited, making evidence-based recommendations..."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Jianpi Qushi Heluo Formula ameliorates podocytes injury related with ROS-mediated NLRP3 inflammasome activation in membranous nephropathy by promoting PINK1-dependent mitophagy. (PubMed, J Ethnopharmacol) - "JQHF can alleviate podocyte damage, that through inhibiting ROS-mediated NLRP3 inflammasome activation by improving PINK1-mediated mitophagy."

Journal • Glomerulonephritis • Metabolic Disorders • Nephrology • Renal Disease • IL1B • IL6 • NLRP3 • NPHS1 • PINK1

Multiomics genetic insights into potential molecular targets for intracranial aneurysm. (PubMed, Stroke Vasc Neurol) - "The study identified key targets for aSAH and uIA, providing insights for developing preventive therapies and advancing research on intracranial aneurysm mechanisms."

Journal • Cardiovascular • Inflammation • Subarachnoid Hemorrhage • Vascular Neurology • PRCP • TNFSF12

The effect of Zuogui-Jiangtang-Yishen decoction on the intestinal flora's response to L-α-phosphatidylcholine and L-tyrosine in patients with diabetic kidney disease: an in vitro study. (PubMed, Front Pharmacol) - "Our previous clinical research also showed that ZGJTYS prevents DKD in a manner similar to that of benazepril...ZGJTYS was found to effectively restore the microbiota that were altered by L-α-phosphatidylcholine and L-tyrosine to normal, along with their metabolites. However, the mechanism by which ZGJTYS exerts its preventive and therapeutic effects on DKD through the gut microbiota still requires further study."

Journal • Preclinical • Diabetic Nephropathy • Nephrology • Renal Disease

Efficacy of Losartan Potassium and Benazepril in Hypertensive Patients With Insulin Resistance: Impact on Blood Pressure, Insulin Sensitivity, and Diabetes Risk. (PubMed, Cureus) - "Conclusions LP was more effective than benazepril in lowering blood pressure and improving insulin sensitivity, which may contribute to a lower diabetes risk in hypertensive patients with IR. A randomized controlled trial with longer follow-up is recommended to confirm these findings and assess long-term metabolic outcomes."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Minimizing STOPP and Beers Criteria Risks in PIM Treatments Using PM-TOM and ChatGPT: A Case Study. (PubMed, Stud Health Technol Inform) - "She was initially prescribed acetaminophen, alendronate, omeprazole, lisinopril, metoprolol, aspirin, citalopram, and vitamin D, which were assessed as inadequate...In the optimized treatment, omeprazole (PPI) was replaced with famotidine (H2-blocker), citalopram (SSRI) with agomelatine (atypical antidepressant), zoledronic acid (bisphosphonate) with denosumab (RANK ligand inhibitor), aspirin (NSAID) with ticagrelor (antiplatelet), and lisinopril with benazepril (ACE inhibitor)...Finally, ChatGPT validated the proposed adjustments, confirming their alignment with the guidelines and highlighting the potential for longer-term benefits. This case study illustrates how a combined use of PM-TOM and AI tools can effectively support the clinical decision-making process by optimizing polypharmacy treatments and minimizing their PIMs, major contributors to morbidity in older adults and high healthcare costs."

Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Gastroesophageal Reflux Disease • Heart Failure • Hypertension • Immunology • Osteoarthritis • Osteoporosis • Pain • Psychiatry • Rheumatology

Description of clinical findings, diagnosis, and treatment of congestive heart failure in 13 goats. (PubMed, J Am Vet Med Assoc) - "Seven goats were treated with cardiac-targeted therapies including β-blockers (n = 2), digoxin (3), benazepril (1), and furosemide (5). Congestive heart failure should be considered in goats presenting with tachycardia, effusions with a normal peripheral total solids concentration, and elevated GGT plasma activity. Although CHF offers a poor prognosis based on the cases in this series, management of CHF is possible."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Solid Tumor • Thymoma • Thymus Cancer

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews. (PubMed, J Clin Med) - "Significant safety signals were detected for amlodipine alone and in combination with aliskiren, specific ACE inhibitors (quinapril, benazepril, trandolapril, fosinopril, perindopril), and certain ARBs (candesartan, losartan). While these results should not discourage appropriate clinical use, they emphasize the importance of monitoring for angioedema, particularly during therapy initiation. The findings from this study need to be validated in prospective studies for further elucidation of the underlying mechanisms."

Adverse events • Journal • Cardiovascular • Hypertension

Modified Huangqi Chifeng decoction alleviates podocyte injury on rat with experimental membranous nephropathy. (PubMed, Ren Fail) - "All rats were divided into four groups: normal group, PHN group, benazepril group (10 mg/kg), and MHCD group (12.5 g/kg), and were treated for 6 weeks...Western blot analysis showed that MHCD increased the expression of nephrin and podocin while inhibiting the activation of NF-κB p65. Our findings indicate that MHCD exert reno-protective effects in the experimental rat model of MN by alleviating podocyte damage and inhibiting the NF-κB pathway."

Journal • Preclinical • Glomerulonephritis • Nephrology • Oncology • Renal Disease • Solid Tumor • Wilms Tumor • NPHS1 • WT1

Benazepril Promotes the Proliferation and Differentiation of Urine-Derived Stem Cells from Children with Nephrotic Syndrome During the Chronic Kidney Disease Stage. (PubMed, Biochem Genet) - "Treatment with 1 μmol/L benazepril enhanced the proliferation and differentiation ability of USCs from NS children, inhibiting the level of inflammation factors, ROS, ACE and Ang2 while promoting ACE2 expression in these cells. This study offers valuable insights for future USCs applications."

Journal • Chronic Kidney Disease • Glomerulonephritis • Inflammation • Nephrology • Pediatrics • Renal Disease • ACE2 • ANGPT2 • AQP1 • CDH1 • IL1B

Centrally Acting ACE Inhibition in SLE (clinicaltrials.gov) - P2 | N=36 | Active, not recruiting | Sponsor: Northwell Health | Recruiting ➔ Active, not recruiting

Enrollment closed • Cognitive Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Clinical studies in Myxomatous Mitral Valve Disease dogs: most prescribed ACEI inhibits ACE2 enzyme activity and ARB increases AngII pool in plasma. (PubMed, Hypertens Res) - "The oral ACE2/Ang1-7 was well tolerated by healthy and MMVD dogs with no adverse events and increased sACE2 activity by 670-755% with ARB (Telmisartan) than with ACEI (Enalapril) background therapy. In vitro rhACE2 activity was inhibited >90% by ACEIs enalapril/benazeprilat at higher doses but lisinopril inhibited at much lower doses...This first report on evaluation of metabolic pools in the RAS pathway identifies surprising interactions between ACEI/ARB/ACE2 and significant changes in key molecular dynamics. Affordable biologics developed in plant cells may offer potential new treatment options for hypertension."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ANGPT1

Targeted delivery of polymeric NO-donor micelles to hepatic stellate cells for restoration of liver function and inhibition of hepatic fibrosis. (PubMed, J Control Release) - "Herein, an elaborate micelle (VN-M@BN) loaded with benazepril (BN) was constructed by self-assembly of polymeric NO donor, aiming for the controlled release of NO in liver fibrosis lesions thereby impeding the progression of liver fibrosis...Furthermore, the in suit antifibrotic treatment results confirmed that VN-M@BN possessed good circulatory stability and targetability to liver fibrotic tissues, thereby effectively ameliorating the collagen deposition and fibrosis process in damaged liver tissues. The NO-based targeted nanodrug system enabled precise delivery of therapeutic drugs to activated HSCs, thereby synergizing the efficacy in treating liver fibrosis with minimal adverse effects."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial Infarction. (PubMed, Int J Gen Med) - "The incidence of adverse reactions was comparable between the two groups (P > 0.05). Sacubitril/Valsartan is a safe and effective treatment for heart failure post-AMI, offering significant improvements in cardiac function, inflammatory response, exercise capacity, and a reduction in MACE risk."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Myocardial Infarction • CRP • IL6

A PopPBPK-RL approach for precision dosing of benazepril in renal impaired patients. (PubMed, J Pharmacokinet Pharmacodyn) - "The use of a PopPBPK model allowed to account for intervariability of patient characteristics and be more inclusive considering also non-frequent patients. Impact analysis of patients' features reveals that renal impairment is the main driver affecting RL capabilities."

Journal • Nephrology • Renal Disease

Repurposed drugs as PCSK9-LDLR disruptors for lipid lowering and cardiovascular disease therapeutics. (PubMed, Mol Divers) - "Finally, the in vitro assay confirmed that Benazepril and Quinapril exhibited the highest potency as PCSK9-LDLR disruptors among the top candidates. These lead compounds have the potential to be repurposed as lipid-lowering agents for the treatment of cardiovascular diseases, offering a promising therapeutic strategy."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Metabolic Disorders

Dose-exposure-response of CARDALIS® (benazepril/spironolactone) on the classical and alternative arms of the renin-angiotensin-aldosterone system in healthy dogs. (PubMed, J Vet Intern Med) - "The combined CARDALIS® product leads to dose-dependent alterations of RAAS metabolites. These results could help inform clinical trials in dogs with heart disease."

Journal • Cardiovascular • Heart Failure